Condition: Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy · Sponsor: Azienda USL Reggio Emilia - IRCCS
The study aims to identify and predict radiopharmaceutical extravasation events using new semi-quantitative parameters and machine learning models. It involves dose rate measurements to develop metrics for real-time monitoring. It also investigates the correlation between extravasation and SUV correction in PET/CT diagnostics, providing an estimate of the correction factor necessary for accurate SUV evaluation in case of an extravasation event.
This description comes directly from the study's public registry record.
Mauro Iori, MD · 0522/296655 · mauro.iori@ausl.re.it
Federica Fioroni, MD · 0522/296653 · federica.fioroni@ausl.re.it
Always discuss trial participation with your own doctor first.
| Azienda USL IRCCS di Reggio Emilia | Reggio Emilia, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07174089